These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1222 related articles for article (PubMed ID: 19808124)

  • 1. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
    Tkaczuk KH
    Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
    Rivera E
    Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
    Murphy CG; Seidman AD
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S58-65. PubMed ID: 19596644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
    Bhushan S; Walko CM
    Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.
    Barnett CM
    Pharmacotherapy; 2009 Dec; 29(12):1482-90. PubMed ID: 19947807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
    Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
    Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
    Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current trends in pharmacotherapy of breast cancer].
    Boér K
    Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
    Perez EA; Patel T; Moreno-Aspitia A
    Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current options in treatment of anthracycline-resistant breast cancer.
    Kröger N; Achterrath W; Hegewisch-Becker S; Mross K; Zander AR
    Cancer Treat Rev; 1999 Oct; 25(5):279-91. PubMed ID: 10544072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixabepilone: clinical role in metastatic breast cancer.
    Denduluri N; Swain S
    Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.
    Roché H; Conte P; Perez EA; Sparano JA; Xu B; Jassem J; Peck R; Kelleher T; Hortobagyi GN
    Breast Cancer Res Treat; 2011 Feb; 125(3):755-65. PubMed ID: 21128114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.